Literature DB >> 26001971

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.

Laurent Créancier1, Isabelle Vandenberghe1, Bruno Gomes1, Caroline Dejean1, Jean-Christophe Blanchet1, Julie Meilleroux2, Rosine Guimbaud3, Janick Selves3, Anna Kruczynski4.   

Abstract

Chromosomal rearrangements of the NTRK1 gene, which encodes the high affinity nerve growth factor receptor (tropomyosin related kinase, TRKA), have been observed in several epithelial cancers, such as colon cancer, papillary thyroid carcinoma or non small cell lung cancer. The various NTRK1 fusions described so far lead to constitutive activation of TRKA kinase activity and are oncogenic. We further investigated here the existence and the frequency of NTRK1 gene rearrangements in colorectal cancer. Using immunohistochemistry and quantitative reverse transcriptase PCR, we analyzed a series of human colorectal cancers. We identified two TRKA positive cases over 408, with NTRK1 chromosomal rearrangements. One of these rearrangements is a TPM3-NTRK1 fusion already observed in colon cancer, while the second one is a TPR-NTRK1 fusion never described in this type of cancer. These findings further confirm that translocations in the NTRK1 gene are recurring events in colorectal cancer, although occurring at a low frequency (around 0.5%).
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Colon cancer; Gene rearrangement; NTRK1; TRKA

Mesh:

Substances:

Year:  2015        PMID: 26001971     DOI: 10.1016/j.canlet.2015.05.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

Review 1.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

Review 2.  Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond.

Authors:  Z Jin; J M Hubbard
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

Review 3.  Precision oncology in metastatic colorectal cancer - from biology to medicine.

Authors:  Federica Di Nicolantonio; Pietro Paolo Vitiello; Silvia Marsoni; Salvatore Siena; Josep Tabernero; Livio Trusolino; Rene Bernards; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2021-04-16       Impact factor: 66.675

Review 4.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

5.  Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Authors:  Lu Wang; Klaus J Busam; Ryma Benayed; Robert Cimera; Jiajing Wang; Ryan Denley; Mamta Rao; Ruth Aryeequaye; Kerry Mullaney; Long Cao; Marc Ladanyi; Meera Hameed
Journal:  J Mol Diagn       Date:  2017-05       Impact factor: 5.568

Review 6.  Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.

Authors:  Benjamin L Solomon; Ignacio Garrido-Laguna
Journal:  Future Oncol       Date:  2018-03-15       Impact factor: 3.404

Review 7.  Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Authors:  Michael Lam; Jonathan M Loree; Allan Anderson Lima Pereira; Yun Shin Chun; Scott Kopetz
Journal:  Curr Treat Options Oncol       Date:  2018-02-27

8.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Authors:  Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins
Journal:  Lancet Oncol       Date:  2018-03-29       Impact factor: 41.316

9.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Authors:  Ryosuke Okamura; Amélie Boichard; Shumei Kato; Jason K Sicklick; Lyudmila Bazhenova; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2018-11-15

10.  OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.

Authors:  Yaogeng Wang; Rolf W Sparidans; Wenlong Li; Maria C Lebre; Jos H Beijnen; Alfred H Schinkel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.